

Current Regulatory Requirements for Conducting Clinical Trials in India for IND/New Drug Version 2.0

Dr. Dhananjay K. Sable
Department of Biotechnology
Indian Institute of Technology, Madras

Lecture – 17 **Content of a Clinical Trial Report**

Hello friends, you are once again welcome to the course Current Regulatory Requirement for Conducting Clinical Trial in India for New Drug and investigational new drug. This is our lecture 17. In our previous lecture, we have seen how to propose a clinical trial protocol. And in this lecture, we are going to see after completion of the clinical trial study, how to report that study that is the content of clinical trial report.

(Refer Slide Time: 00:46)



LEARNING OBJECTIVES

The faculty will cover the following in this lecture:

- ☐ What is a study report?
- ☐ How to prepare it?
- ☐ What should be the contents?
- ☐ Detail content to be submitted as per regulation.
- ☐ How to address about investigational plan, SAE, AE, EC etc.?



So, after completion of the lecture the learners will come to know, what is means by study report? How to prepare it? What should be the content? The detail content to be submitted as per the regulation that is what the regulatory authority expect to submit. How to address about the investigational product investigational plan? How to report the SAE adverse event? How to write about the ethics committee and the other things?

(Refer Slide Time: 00:26)



The slide features the CDSA logo on the top left and the NPTEL logo on the top right. Below the logos, the word "REPORT" is centered in a large, bold, blue font. The main content of the slide is a blue rectangular box containing two numbered points. To the right of this box, there is a small video inset showing a man with a mustache, wearing a dark suit and a light-colored shirt, speaking. At the bottom of the slide, a dark blue banner contains the text "CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)".

REPORT

1. The clinical study **report** described here is an "integrated" full report of an individual study of any therapeutic, prophylactic or diagnostic agent conducted in patients, in which the clinical and statistical description, presentations, and analyses are integrated into a single report, incorporating tables and figures.
2. Appendices containing the protocol, sample, case report forms, investigator related information, information related to the test drugs/investigational products etc.

CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)

So, let us move to our report. The clinical study report described here is an “integrated” full report of an individual study of any therapeutic, prophylactic or diagnostic agent conducted in patients, in which the clinical and statistical description, presentation and analysis are integrated into a single report incorporating tables and the figures.

The appendices containing the protocol, sample, case report forms, investigator related information, information related to the test drug, investigational plan, then the investigational product and the other things.

(Refer Slide Time: 02:08)



CDSA

REPORT

The full integrated **report** of the individual study should include the most detailed discussion of individual adverse events or laboratory abnormalities, but these should usually be reexamined as part of an overall safety analysis of all available data in any application.

NPTEL

CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)

The full integrated report of the individual study should include the most detailed discussion of individual adverse events or laboratory abnormalities. But these should usually be reexamined as part of an overall safety analysis of all available data in any application.

(Refer Slide Time: 02:35)



RULE POSITION

1. NDCT Rules, 2019 THIRD SCHEDULE (see rules 8, 10, 11, 25, 35, 42 and 49) prescribed under TABLE-6 "STRUCTURE, CONTENT AND FORMAT FOR CLINICAL TRIAL REPORT".
2. Data should be presented in the report at different levels of detail: Overall summary figures, and tables for important demographic, efficacy and safety variables may be placed in the text to illustrate important points.




CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)

Let us see what is the rule position and where it has been given in our New Drug Clinical Trial Rules 2019. So, it is given in the Third Schedule of New Drug and Clinical Trial Rule. If you would like, you can refer the rules 8 rule, 10, 11, 25, 35, 42 and 49.

In the third schedule that TABLE-6 it mentions the "structure content and format for clinical trial report". So, the data should be presented in the report at different level of details: The overall summary figures, and tables for important demographic, efficacy and safety variables maybe placed in the text to illustrate important points.

(Refer Slide Time: 03:27)



The slide features the CDSA logo on the top left and the NPTEL logo on the top right. Below these logos are four colored squares: blue, grey, light blue, and dark blue. The main title of the slide is "NDCT RULES, 2019" followed by "CONTENT OF CT REPORT". A blue rectangular box contains a numbered list of three items. To the right of this box is a small video inset showing a man with a mustache, wearing a dark suit and a light-colored shirt, speaking. At the bottom of the slide, there is a dark blue banner with white text.

1. Title page: This contain information about the title of the study, the protocol code, name of the investigational product tested, development Phase, indication studied, a brief description of the trial design, the start and end date of patient accrual and the names of the Sponsor and the participating Institutes (Investigators).

2. Study synopsis: A brief overview of the study from the protocol development to the trial closure and summarize the important conclusions derived from the study.

3. Statement of compliance with the Good Clinical Practices Guidelines.

CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)

Let us move towards the actual content of the clinical trial report and how it should be.

The first what we have seen in our previous lecture in that propose clinical trial report also that was the title page. Here also it is a title page and this title page this should contain information about the title of the study, whether it is double blinded, single blinded. Then the protocol code, name of the investigational product tested, the product which is use here during that clinical trial then indication, for which it has been study, a brief description of the trial design the start and end date of patient accrual and the names of the sponsor and participating institutes that is the investigators.

The study synopsis, it should be in a brief that is 1-2 page. A brief overview of the study from the protocol development to the trial closure and it should summarize the important conclusion derived from the study. Then the statement of compliance require to be given that

whatever the study the sponsor investigator they have performed that was as per the good clinical practices guideline and norms; that statement of compliance required to be submitted.

Then list of abbreviation and definition. For example, IP it is Investigational Product, AE Adverse Event. So, all the abbreviations use and it is definition that has to be given, then table of content required to be given.

(Refer Slide Time: 05:05)



The slide displays the following content:

- 4. List of abbreviations and definitions
- 5. Table of Content
- 6. **Ethics committee:** This section should document that the study was conducted in accordance with the ethical principles of Declaration of Helsinki. A detailed description of the Ethics Committee constitution and dates of approvals of trial documents for each of the participating sites should be provided.
- 7. **Study team:** Briefly describe the administrative structure of the study (Investigators, site staff, Sponsor or designates, Central laboratory etc.).

At the bottom of the slide, it reads: CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)

Next to this the detail of the ethics committee which has accorded the approval and this section should document that the study was conducted in accordance with the ethical principles of given in the declaration of Helsinki. Then a detailed description of the ethics committee constitution and dates of approval of trial document for each of the participating sites should be provided.

A declaration it should state that ethics committee notification as per good clinical practice guideline, ethical guideline for biomedical research and human subject we should by ICMR have been followed. So, in case of it is a; if it is a research for the biomedical and health, then the respective ethics committee approval should be there. And in case of the chemical trial the ethics can be registration from the central licensing authority we have seen in our previous lecture. Then regarding the study team, briefly required to describe the administrative structure of the study including investigators involved the site staff, then sponsor or his designates and the central laboratory which are involved.

(Refer Slide Time: 06:30)



The slide is titled "NDCT RULES, 2019 CONTENT OF CT REPORT". It features logos for CDSA (Central Drug Standardization Authority) and HPTEL (Health Protection and Training Institute) at the top. The main content is a list of requirements for the Clinical Trial Report, numbered 8 through 10. A small inset image of a man in a suit is visible in the bottom right corner of the slide.

- 8. **Introduction:** A brief description of the product development rationale should be given here.
- 9. **Study objective:** A statement describing the overall purpose of the study and the primary and secondary objectives to be achieved should be mentioned here.
- 10. **Investigational plan:** This section should describe the overall trial design, the Subject selection criteria, the treatment procedures, blinding or randomization techniques if any, allowed or disallowed concomitant treatment, the efficacy and safety criteria assessed, the data quality assurance procedures and the statistical methods planned for the analysis of the data obtained.

CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)

In the introduction part, a brief description of the product development rationale should be given. Then the study objective in this regard a statement describing the overall purpose of the study and the primary and secondary objective to be achieve should be mentioned. Under the investigational plan, this section should describe the overall trial design, in the subject selection

criteria, the treatment procedure followed blinding or randomization techniques if employed any and the efficacy and safety criteria assessed, the data quality assurance procedure and the statistical method plan for the analysis of the data obtained.

(Refer Slide Time: 07:16)

The slide is titled "NDCT RULES, 2019 CONTENT OF CT REPORT". It features the CDSA logo on the top left and the NPTEL logo on the top right. Below the logos are four colored squares: blue, grey, light blue, and dark blue. The main content is a blue box with white text containing two numbered points:

- 11. Trial subjects:** A clear accounting of all trial subjects who entered the study will be given here. Mention should also be made of all cases that were dropouts or protocol deviations. Enumerate the patients screened, randomized, and prematurely discontinued. State reasons for premature discontinuation of therapy in each applicable case.
- 12. Efficacy evaluation:** The results of evaluation of all the efficacy variables will be described in this section with appropriate tabular and graphical representation.

Below these points, it states: "A brief description of the demographic characteristics of the trial patients should also be provided along with a listing of patients and observations excluded from efficacy analysis."

At the bottom of the slide, there is a video feed of a man in a suit, and a footer that reads: "CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)".

With respect to that trial subject, a clear accounting of all trial subjects who entered the study will have to be given and there should be a mention also to be made of all cases that were dropout or protocol deviations. Then enumerate the patients screened, randomize, and prematurely discontinued. State the reason for premature discontinuation of therapy in each applicable case.

Under the efficacy evaluation, the result of evaluation of all the efficacy variables will be described in this sections with appropriate tabular and graphical representation. A brief

description of the demographic characteristic of the trial patients should also be provided along with a listing of patient and observation excluded from efficacy analysis.

(Refer Slide Time: 08:10)

**NDCT RULES, 2019
CONTENT OF CT REPORT**

13. Safety evaluation: This section should include the complete list of:

1. All SAE, whether expected or unexpected and
2. Unexpected AE whether serious or not

The comparison of adverse events across study groups may be presented in a tabular or graphical form.


14. Discussion and overall conclusion: Discussion of the important conclusions derived from the trial and scope for further development.

CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)

Then with respect to the safety evaluation, this section should include the complete list of; all SAEs whether expected or unexpected that should be included.

Unexpected AEs that is adverse event whether serious or not that also required to be noted down. The comparison of adverse event across study groups may be presented in a tabular or graphical form. Then the discussion and overall conclusion in this section the: discussion of the important conclusion derive from the trial and scope for further development required to be give. Then for the study whatever the list of references, which they have preferred and they have used during the study that list trial of the references required to be given.

(Refer Slide Time: 09:59)



The slide features the CDSA logo on the top left and the NPTEL logo on the top right. Below the logos are four colored squares: blue, grey, light blue, and dark blue. The title 'NDCT RULES, 2019' is centered above 'CONTENT OF CT REPORT'. A blue box contains the following text:

15. List of references:


16. **Appendices:** List of appendices to the Clinical Study Report (CSR)

- (a) Protocol and amendments
- (b) Specimen of Case Record Form (CRF)
- (c) Investigators' names with contact addresses, phone, e-mail etc.
- (d) Patient data listings
- (e) List of trial participants treated with investigational product
- (f) Discontinued participants
- (g) Protocol deviations

A small video inset of a man in a suit is visible on the right side of the slide. At the bottom, a dark blue bar contains the text: 'CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)'.

The next part is the appendices. In this section, the list of appendices to the clinical study report like a protocol and amendments, specimen of the Case Record Form, investigator name with contact address, phone, e-mail and the details of the investigator, then the patient data listing, the list of trial participant treated with investigational product that list has to be submitted. Also the participants those you have discontinued withdrawn that require to be given. If there are any protocol deviation that is also, required to be submitted.

(Refer Slide Time: 09:37)



The slide features the CDSA logo on the top left and the NPTEL logo on the top right. Below these logos, the title "NDCT RULES, 2019" is displayed in bold, followed by "CONTENT OF CT REPORT" in a slightly smaller bold font. A blue rectangular box contains a list of items: (h) Case Record Forms of cases involving death and life threatening adverse event cases, (i) Publications from the trial, (j) Important publications referenced in the study, (k) Audit certificate, if available, and (l) Investigator's certificate that he/she has read the report and that the report accurately describes the conduct and the results of the study. A small video inset of a man in a suit is positioned in the bottom right corner of the slide area. At the very bottom, a dark blue banner contains the text "CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)".

NDCT RULES, 2019
CONTENT OF CT REPORT

- (h) Case Record Forms of cases involving death and life threatening adverse event cases
- (i) Publications from the trial
- (j) Important publications referenced in the study
- (k) Audit certificate, if available
- (l) Investigator's certificate that he/she has read the report and that the report accurately describes the conduct and the results of the study.

CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)

In the case require form of cases involving death and life threatening adverse event cases that is required to be given. Then publication from the trial if after the trial any publication has been made that is a required to be submit important publication reference in the study if the data regarding the trial subject, or the design, or the product that has been sited from the references, then the important publication that should be given.

Audit certificate if available; if any authority has audited the site and if any audit certificate is available, then that is also required to be attach with the report. Investigators certificate that he or she has read the report and that the report accurately describe the conduct and the results of the certificate. So, this certificate has to be attached with that that the investigator that he has read all the reports and it is a correct to his or her knowledge.

(Refer Slide Time: 10:42)



SUMMARY

In lecture 17 (L17), we briefly learnt about:

- What is a study report?
- How to report a clinical trial?
- The position in regulation
- What should be the data elements?




CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)

So, this is about the lecture let us have the summary for this lecture.

So, in this lecture we have seen, what is the study report? How to prepared the clinical trial study report? What should be the data element? The what is the position of this content of the report in drug and cosmetic and new drug and clinical trial rule regulation. We have seen about the data management and the other things.

Let us have the quick recap.

(Refer Slide Time: 11:25)



The slide is titled "RECAP" and features three numbered questions. At the top left is the CDSA logo, and at the top right is the NPTEL logo. The questions are as follows:

- 1** State true or false
The structure, content and format for clinical trial report are given in the NDCT rules, Third Schedule, Table-6.
True
- 2** Who prepares the clinical trial study report ?
Investigator and his team
- 3** Fill in the blank
Clinical Trial Report is prepared in compliance to _____ Guidelines.
GCP

A small video inset of a man in a suit is visible on the right side of the slide. At the bottom, a blue bar contains the text: "CURRENT REGULATORY REQUIREMENTS FOR CONDUCTING CLINICAL TRIALS IN INDIA FOR IND/NEW DRUG (VERSION 2.0)".

The question for you is the structure and content and format for clinical trial report are in NDCT rules. So, you have to tell whether it is true or false, whether the structure content and format for clinical trial report are given in NDCT rules So, this is true, the structure content and format given in the NDCT rule we have seen it is in the Third Schedule.

The next question who prepares clinical trial study report? So, it is the responsibility of investigator and his team who prepare the clinical trial study report. Clinical trial report compliance as per the which guideline it has to be; so it is as per the good clinical practices guideline and as per the NDCT rule 2019.

So, this is all about the clinical trial report. In previous lecture we have seen content of propose report. Now, I hope you are capable of proposing clinical trial in proper format, with a proper content and was this study completed, you would be able to report it to the licensing

authority. So, we will see some next other things in our next lecture. Till then thank you for watching the video. Bye, bye and take care.